Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för fotemustine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2016-03-06

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.

Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E.

Neuro Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1093/neuonc/now035

Bibliografisk träff 2016-02-01

Nitrosoureas in the Management of Malignant Gliomas.

Brandes AA, Bartolotti M, Tosoni A, Franceschi E.

Curr Neurol Neurosci Rep · review; journal article · DOI 10.1007/s11910-015-0611-8

Bibliografisk träff 2015-11-05

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.

Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J.

Clin Transl Oncol · journal article · DOI 10.1007/s12094-015-1444-2

Bibliografisk träff 2015-10-12

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A.

Br J Haematol · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1111/bjh.13803

Bibliografisk träff 2015-08-12

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G, Maio M.

Oncoimmunology · research-article; journal article · DOI 10.1080/2162402x.2015.1071007

Bibliografisk träff 2015-02-22

Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.

Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Esposito V, Enrici RM.

J Neurooncol · journal article · DOI 10.1007/s11060-015-1745-x

Bibliografisk träff 2014-12-23

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M.

Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1093/annonc/mdu577

Bibliografisk träff 2014-03-31

An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.

Lombardi G, Farina P, Della Puppa A, Cecchin D, Pambuku A, Bellu L, Zagonel V.

Biomed Res Int · research-article; review; journal article · DOI 10.1155/2014/698542

Bibliografisk träff 2013-09-01

Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.

De Felice F, Bulzonetti N, Musio D, D'Elia A, Salvati M, Tombolini V.

Anticancer Res · journal article

Bibliografisk träff 2013-04-08

Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.

Addeo R, Zappavigna S, Luce A, Facchini S, Caraglia M.

Expert Opin Drug Saf · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14740338.2013.789017

Bibliografisk träff 2004-03-01

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y.

J Clin Oncol · clinical trial, phase iii; comparative study; clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2004.04.165

Bibliografisk träff 1989-11-01

Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036.

Tapiero H, Yin MB, Catalin J, Paraire M, Deloffre P, Rustum Y, Bizzari JP, Tew KD.

Anticancer Res · research support, non-u.s. gov't; journal article